Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Myriad Genetics Inc (MYGN)

In Vitro & In Vivo Diagnostic Substances

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

322 NORTH 2200 WEST
SALT LAKE CITY, UT

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/06/1995

Market Cap

2,568,400,912

Shares Outstanding

82,200,000

Weighted SO

89,639,379

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

GH --.--%

CDNA --.--%

NVTA --.--%

CSTL --.--%

SHC --.--%

SYNH --.--%

NEOG --.--%

RDNT --.--%

NTRA --.--%

Beta

1.9600

Last Div

0.0000

Range

13.82-28.9

Chg

0.4300

Avg Vol

787462

Mkt Cap

2568400912

Exch

NASDAQ

Country

US

Phone

801 584 3600

DCF Diff

30.8679

DCF

-2.6779

Div Yield

0.0000

P/S

4.6144

EV Multiple

-14.8747

P/FV

3.3822

Div Yield %

0.0000

P/E

-9.9587

PEG

0.0335

Payout

0.0000

Current Ratio

1.2680

Quick Ratio

1.1481

Cash Ratio

0.3631

DSO

75.5444

DIO

52.4714

Op Cycle

128.0157

DPO

70.8677

CCC

57.1480

Gross Margin

0.6863

Op Margin

-0.4060

Pretax Margin

-0.4130

Net Margin

-0.4170

Eff Tax Rate

-0.0013

ROA

-0.2020

ROE

-0.3089

ROCE

-0.2405

NI/EBT

1.0096

EBT/EBIT

1.0173

EBIT/Rev

-0.4060

Debt Ratio

0.1753

D/E

0.2947

LT Debt/Cap

0.2118

Total Debt/Cap

0.2276

Int Coverage

-113.0000

CF/Debt

-0.2790

Equity Multi

1.6814

Rec Turnover

4.8316

Pay Turnover

5.1504

Inv Turnover

6.9562

FA Turnover

2.4771

Asset Turnover

0.4844

OCF/Share

-0.6876

FCF/Share

-1.4192

Cash/Share

1.0559

OCF/Sales

-0.1010

FCF/OCF

2.0641

CF Coverage

-0.2790

ST Coverage

-3.1573

CapEx Coverage

-0.9398

Div&CapEx Cov

-0.9398

P/BV

3.3822

P/B

3.3822

P/S

4.6144

P/E

-9.9587

P/FCF

-22.1414

P/OCF

-41.1284

P/CF

-41.1284

PEG

0.0335

P/S

4.6144

EV Multiple

-14.8747

P/FV

3.3822

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Feb 26, 01:30 Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. GlobeNewswire Inc. Feb 18, 23:30 Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research GlobeNewswire Inc. Jan 27, 02:57 Myria and Beacher’s Madhouse to Bring an Unforgettable Spectacle to New Orleans During Big Game Weekend GlobeNewswire Inc. Dec 10, 23:26 Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing GlobeNewswire Inc. Nov 17, 21:00 MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights GlobeNewswire Inc. Aug 02, 05:30 EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS GlobeNewswire Inc. Jan 18, 18:10 Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics Benzinga Dec 21, 13:05 Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation GlobeNewswire Inc. Dec 21, 08:30 Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance GlobeNewswire Inc. Nov 08, 21:20 Myriad Genetics Announces Pricing of Upsized Offering of Common Stock GlobeNewswire Inc. Nov 08, 21:20 Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
1.75 07/01/2009 11/30/-0001 11/30/-0001 11/30/-0001
1.75 06/15/2009 11/30/-0001 11/30/-0001 11/30/-0001